Companies and Markets
Call us on +44 (0) 203 086 8600
Market Research A to Z | Company Profiles A to Z | RegisterRegister | Contact UsContact Us | Shopping Basket Shopping Basket
+44 (0) 203 086 8600 Call us on

Drugs and Treatments for Autoimmune Diseases: Global Markets (Market Research Report)

3889.12

Select License Type

Electronic License

Electronic License

An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.

£3,889.12

Change Currency

GBP EURO USD

Market

Healthcare and Medical

Report Type

Market Research

Country

Global

Published

18 October 2011

Number of Pages

154

Report Delivery

Email

Delivery Lead Time

1-3 hours, 24 hour max

Publisher

BCC Research

File Format

PDF

Rheumatoid arthritis is the single most common disease of the auto-immune system and is one of the most attractive therapy areas in the auto-immune pharmaceutical industry. Over the last decade, the introduction of biologics has propelled growth in the market and with unmet clinic need, the auto-immune industry is set for further growth.

The market is is dominated by agents that inhibit TNF-alpha and these include Remicade, Humira and Enbrel, generating over $10 billion in revenues. Additional agents include MabThera, Orencia, Cimzia and Actemra (for RA).

The global market for autoimmune treatments reached at $34 billion in 2010, it is expected to reach at $38.9 billion by 2011 and it will further grow to $55 billion by 2016 at a compounded annual growth rate (CAGR) of 7.2%. The U.S is the largest market for autoimmune treatments and holds 43% share in the global market. It will sustain its position and will hold 44% market share in 2016. Europe remains the second largest market for autoimmune treatments and holds 27% share in the global market. It will sustain its position and will hold 28% market share in 2016.

The global market for autoimmune therapeutics was estimated at more than $34 billion in 2010, with mid-single-digit growth through 2016. Different segments such as arthritis and psoriasis treatments are projected to grow at a faster rate than other treatments. The report will analyze the global markets by region and by disease, and then provide growth projections for each region and/or disease.

Autoimmune diseases arise from an overactive immune response by the body against substances and tissues normally present in the body. An autoimmune reaction can be triggered by a foreign substance entering the body; an alteration of normal body substances through a virus, drug, sunlight, or radiation; a malfunctioning of cells that control antibody production within the body; and genetic predisposition.

Autoimmune diseases afflict individuals with symptoms presented in the neurological, musculoskeletal, dermatological, and gastrointestinal areas of the body. Women are more likely to have autoimmune disorders than men, and research is ongoing to determine why these diseases target women of all ages.

This report is designed to investigate the autoimmune market by disease and by treatment, with supporting tables and figures to illustrate projected growth. The report will include the U.S., Europe, Japan, and other countries such as China and India.

This report offers forecasts by product segment, disease, and geographical region from 2011 through 2016, including supporting analyses for projections. This report is a valuable tool for anyone assessing the autoimmune market and attempting to devise a strategy for successful competition within it. It provides a thorough background on the structure of the autoimmune market and the chief challenges and opportunities it faces. It offers the information necessary for understanding the current market and for addressing the emerging one.

 

Speak to an Advisor

Call us on
+44 (0) 203 086 8600

Select License Type

Electronic License

Electronic License

An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.

£3,889.12

Change Currency

GBP EURO USD

Change Currency

GBP
USD

Visitor Comments

All posts are pre-moderated and must obey the house rules.

Change Currency

GBP
USD

Change Currency

GBP
USD

Use our research skills: Get free support

Free Research Support: Let us do the work for you and find information from public and private sources of information. Contact us now and we can save you time and money.......Free Research Support

eBrandPromote: Get your brands ranked highly online

eBrandPromote: Let us promote your brand online through article writing, press release distribution, social media and search engine marketing services. Click here to download our eBrandPromote brochure.

Accessibility
Close

Contrast settings

Text size settings